I Want So Much to Live, a 2009 documentary about the genesis of Genentech’s breast cancer drug Herceptin, offers a wealth of detail about the discovery and development challenges faced by makers of ...

Genentech Inc. said Monday that its drug Herceptin prolonged the lives of breast cancer patients in two large clinical trials, setting the stage for a new way to treat the disease. The drug ...

A new study has shown that heart failure risk does not increase over time among patients who take Genentech's breast cancer drug Herceptin, the company announced Sunday. Approximately 4.1% of ...

SAN FRANCISCO (MarketWatch) -- Genentech Inc. late Friday said the Food and Drug Administration has extended the review of its application seeking approval for expanded use of its Herceptin drug ...

Genentech Inc. prevailed over Chiron Corp. on Friday in a patent dispute concerning rights to one of Genentech’s best-selling medicines, the breast cancer drug Herceptin. A federal court jury in ...

BOSTON (MarketWatch) -- Genentech said Wednesday it has applied to U.S. regulators to have its breast cancer drug Herceptin approved to treat early-stage breast cancer. According to the company ...

In the PHranceSCa study, Genentech is currently investigating patient preference for SC administration of the FDC compared to standard IV administration of Perjeta and Herceptin in people with ...

Genentech's Herceptin announcement also breaks new medical and scientific ground. When the biotech giant won approval for Herceptin in 1998, the company agreed to test breast cancer patients to ...

In the fourth quarter, Genentech will continue to enjoy easy year-over-year comparisons and outsized gains in its Avastin and Herceptin product lines. These products began to experience expanded ...

Genentech is considered a biotech powerhouse with blockbuster cancer drugs Rituxan, Herceptin and Avastin. Swiss-based Roche purchased a majority stake in Genentech in 1990 and later acquired the ...